Table 1 Patient characteristics (n = 44)
Median age, years (range) | 71 (49–86) |
|---|---|
Gender Male/female | 19/25 |
Performance status | Â |
0 | 24 (54.5) |
1 | 14 (31.8) |
2 | 4 (9.1) |
≥3 | 2 (4.5) |
Type of M protein n (%) | Â |
IgG | 22 (50.0) |
IgA | 10 (22.7) |
IgD | 1 (2.3) |
BJP | 10 (22.7) |
No secreted | 1 (2.3) |
Durie-Salmon stage n (%) | Â |
I | 4 (9.1) |
II | 6 (13.6) |
III | 34 (77.3) |
ISS stage n (%) | Â |
1 | 10 (22.7) |
2 | 11 (25.0) |
3 | 23 (52.3) |
No. genetic abnormalities of 13q deletion n (%) | Â |
Yes | 6 (13.6) |
No | 38 (86.4) |
No. of stem cell transplantation n (%) | Â |
Yes | 15 (34.1) |
No | 29 (65.9) |
No. of prior treatment regimens* n (%) 09 (20.5) | Â |
1 | 16 (36.4) |
2 | 7 (15.9) |
≥3 | 12 (27.3) |
Type of prior treatment regimens n (%) | Â |
VAD | 22 (25.9) |
MP | 19 (22.4) |
HDD | 10 (11.8) |
Thalidomide | 9 (10.6) |
Stem cell transplantation | 5 (5.9) |
CP | 5 (5.9) |
ROAD | 4 (4.7) |
Cyclophosphamide alone | 3 (3.5) |
DEX pulse | 2 (2.4) |
MD | 2 (2.4) |
INF α-MP | 2 (2.4) |
CAD | 1 (1.2) |
RD | 1 (1.2) |